Concepts (220)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 37 | 2024 | 131 | 7.220 |
Why?
|
| Prostatic Neoplasms | 8 | 2024 | 31 | 2.750 |
Why?
|
| Neoplasms | 8 | 2023 | 147 | 1.860 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 32 | 1.400 |
Why?
|
| Neoplasm Staging | 8 | 2023 | 50 | 1.310 |
Why?
|
| South Africa | 45 | 2025 | 7596 | 1.310 |
Why?
|
| Humans | 61 | 2025 | 14537 | 1.190 |
Why?
|
| HIV Infections | 14 | 2024 | 5097 | 1.110 |
Why?
|
| Prostate-Specific Antigen | 2 | 2023 | 10 | 1.110 |
Why?
|
| Middle Aged | 30 | 2025 | 3601 | 1.040 |
Why?
|
| Female | 47 | 2025 | 9103 | 1.020 |
Why?
|
| Aged | 18 | 2025 | 1740 | 0.960 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 43 | 0.910 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 39 | 0.910 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 2 | 0.910 |
Why?
|
| Focus Groups | 1 | 2024 | 196 | 0.870 |
Why?
|
| Qualitative Research | 1 | 2024 | 321 | 0.820 |
Why?
|
| Noncommunicable Diseases | 1 | 2023 | 77 | 0.810 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 262 | 0.790 |
Why?
|
| Tobacco Use Cessation | 1 | 2020 | 3 | 0.700 |
Why?
|
| Attitude to Health | 1 | 2020 | 56 | 0.680 |
Why?
|
| Adult | 23 | 2025 | 5913 | 0.650 |
Why?
|
| Receptor, ErbB-2 | 7 | 2023 | 17 | 0.630 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 239 | 0.600 |
Why?
|
| Age of Onset | 1 | 2018 | 32 | 0.600 |
Why?
|
| Prospective Studies | 12 | 2024 | 1160 | 0.580 |
Why?
|
| Male | 19 | 2025 | 6754 | 0.550 |
Why?
|
| Terminal Care | 4 | 2020 | 35 | 0.510 |
Why?
|
| Case-Control Studies | 9 | 2024 | 480 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2024 | 176 | 0.480 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 106 | 0.450 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 468 | 0.430 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 198 | 0.420 |
Why?
|
| Receptors, Progesterone | 5 | 2023 | 14 | 0.390 |
Why?
|
| Cohort Studies | 10 | 2023 | 967 | 0.380 |
Why?
|
| Diet | 3 | 2021 | 109 | 0.370 |
Why?
|
| Terminally Ill | 3 | 2019 | 21 | 0.350 |
Why?
|
| Receptors, Estrogen | 4 | 2021 | 14 | 0.340 |
Why?
|
| Diabetes Mellitus | 2 | 2023 | 146 | 0.330 |
Why?
|
| Mastectomy | 2 | 2020 | 10 | 0.310 |
Why?
|
| Carcinoma | 2 | 2018 | 9 | 0.310 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 14 | 0.310 |
Why?
|
| Ki-67 Antigen | 3 | 2023 | 13 | 0.280 |
Why?
|
| Risk Factors | 8 | 2022 | 1475 | 0.270 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2025 | 3 | 0.270 |
Why?
|
| Hypertension | 2 | 2023 | 419 | 0.270 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 5 | 0.270 |
Why?
|
| Hospitals, Public | 2 | 2018 | 45 | 0.270 |
Why?
|
| Prevalence | 5 | 2022 | 1192 | 0.270 |
Why?
|
| Chronic Disease | 2 | 2023 | 107 | 0.260 |
Why?
|
| Developing Countries | 3 | 2024 | 400 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 33 | 0.260 |
Why?
|
| Multimorbidity | 2 | 2023 | 42 | 0.250 |
Why?
|
| Culture | 1 | 2024 | 23 | 0.240 |
Why?
|
| Urban Population | 3 | 2024 | 257 | 0.240 |
Why?
|
| Immunohistochemistry | 2 | 2023 | 26 | 0.240 |
Why?
|
| Palliative Care | 3 | 2020 | 52 | 0.240 |
Why?
|
| Africa South of the Sahara | 5 | 2024 | 353 | 0.240 |
Why?
|
| Social Stigma | 1 | 2024 | 80 | 0.230 |
Why?
|
| Medical Assistance | 1 | 2023 | 8 | 0.230 |
Why?
|
| Feeding Behavior | 2 | 2021 | 60 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 32 | 0.220 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2023 | 4 | 0.220 |
Why?
|
| Leukopenia | 1 | 2023 | 4 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2023 | 106 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 9 | 0.220 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 9 | 0.210 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 74 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2022 | 2 | 0.210 |
Why?
|
| Obesity | 3 | 2023 | 367 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 12 | 0.210 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 9 | 0.210 |
Why?
|
| Health Services Accessibility | 4 | 2024 | 280 | 0.210 |
Why?
|
| Glucose | 1 | 2022 | 45 | 0.210 |
Why?
|
| Cholesterol | 1 | 2022 | 38 | 0.210 |
Why?
|
| Prognosis | 5 | 2023 | 199 | 0.200 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 115 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 256 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2023 | 19 | 0.200 |
Why?
|
| Death | 2 | 2019 | 14 | 0.200 |
Why?
|
| Malignant Hyperthermia | 2 | 1992 | 2 | 0.190 |
Why?
|
| Obesity, Abdominal | 1 | 2021 | 19 | 0.190 |
Why?
|
| Breast | 2 | 2021 | 10 | 0.190 |
Why?
|
| Mitotic Index | 1 | 2021 | 1 | 0.190 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2021 | 17 | 0.180 |
Why?
|
| Delphi Technique | 1 | 2021 | 30 | 0.180 |
Why?
|
| Consensus | 1 | 2021 | 62 | 0.180 |
Why?
|
| Caregivers | 2 | 2019 | 76 | 0.180 |
Why?
|
| Urban Health | 1 | 2021 | 78 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2020 | 3 | 0.170 |
Why?
|
| Young Adult | 4 | 2020 | 2498 | 0.170 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 62 | 0.160 |
Why?
|
| Quality of Health Care | 1 | 2019 | 62 | 0.160 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 14 | 0.160 |
Why?
|
| Comorbidity | 4 | 2020 | 188 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Patient Preference | 1 | 2018 | 30 | 0.150 |
Why?
|
| United States | 3 | 2025 | 132 | 0.150 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 1422 | 0.150 |
Why?
|
| Mastectomy, Segmental | 1 | 2017 | 3 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2022 | 163 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 167 | 0.130 |
Why?
|
| Odds Ratio | 4 | 2021 | 133 | 0.130 |
Why?
|
| Age Factors | 4 | 2019 | 370 | 0.130 |
Why?
|
| Genotype | 3 | 2023 | 442 | 0.130 |
Why?
|
| Muscles | 2 | 1992 | 3 | 0.120 |
Why?
|
| Travel | 1 | 2014 | 21 | 0.110 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2025 | 9 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2023 | 7 | 0.110 |
Why?
|
| Tamoxifen | 2 | 2023 | 9 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 25 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2024 | 149 | 0.100 |
Why?
|
| Genetics, Population | 2 | 2024 | 52 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 370 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 1991 | 2 | 0.090 |
Why?
|
| Protein Kinases | 1 | 1991 | 4 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 265 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 1324 | 0.080 |
Why?
|
| Adolescent | 3 | 2022 | 2985 | 0.080 |
Why?
|
| Delayed Diagnosis | 2 | 2020 | 17 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 96 | 0.080 |
Why?
|
| Prostate | 2 | 2018 | 4 | 0.080 |
Why?
|
| Incidence | 2 | 2021 | 685 | 0.070 |
Why?
|
| Logistic Models | 2 | 2019 | 254 | 0.070 |
Why?
|
| Viral Load | 2 | 2022 | 819 | 0.070 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 15 | 0.070 |
Why?
|
| Population Groups | 2 | 2017 | 9 | 0.060 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2025 | 1 | 0.060 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2025 | 1 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 411 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 1 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2024 | 11 | 0.060 |
Why?
|
| DNA Methylation | 1 | 2024 | 19 | 0.060 |
Why?
|
| Gene Frequency | 1 | 2024 | 122 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2024 | 34 | 0.060 |
Why?
|
| Alleles | 1 | 2024 | 143 | 0.060 |
Why?
|
| Papillomaviridae | 1 | 2024 | 34 | 0.060 |
Why?
|
| Haplotypes | 1 | 2024 | 125 | 0.060 |
Why?
|
| Filgrastim | 1 | 2023 | 4 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 2 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 16 | 0.050 |
Why?
|
| Macrophages | 1 | 2023 | 15 | 0.050 |
Why?
|
| RNA | 1 | 2023 | 26 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 99 | 0.050 |
Why?
|
| Diet Surveys | 1 | 2021 | 7 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 29 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 60 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 25 | 0.050 |
Why?
|
| Reproductive History | 1 | 2021 | 2 | 0.050 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2021 | 8 | 0.050 |
Why?
|
| Research Report | 1 | 2021 | 11 | 0.050 |
Why?
|
| Menopause | 1 | 2021 | 24 | 0.050 |
Why?
|
| Life Style | 1 | 2021 | 86 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2020 | 11 | 0.040 |
Why?
|
| Spirituality | 1 | 2020 | 11 | 0.040 |
Why?
|
| HIV | 1 | 2023 | 380 | 0.040 |
Why?
|
| Rural Population | 1 | 2024 | 654 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 321 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2020 | 28 | 0.040 |
Why?
|
| Pain | 1 | 2020 | 41 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 26 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 18 | 0.040 |
Why?
|
| Mitral Valve Prolapse | 1 | 1999 | 1 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 1999 | 10 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 563 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Social Support | 1 | 2020 | 77 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 114 | 0.040 |
Why?
|
| Meat | 1 | 2019 | 3 | 0.040 |
Why?
|
| Fruit | 1 | 2019 | 5 | 0.040 |
Why?
|
| Attitude to Death | 1 | 2019 | 6 | 0.040 |
Why?
|
| Vegetables | 1 | 2019 | 8 | 0.040 |
Why?
|
| Premenopause | 1 | 2019 | 14 | 0.040 |
Why?
|
| Epirubicin | 1 | 2018 | 2 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2018 | 8 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2018 | 19 | 0.040 |
Why?
|
| Baltimore | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 225 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 107 | 0.040 |
Why?
|
| Home Nursing | 1 | 2018 | 8 | 0.040 |
Why?
|
| Emotions | 1 | 2018 | 18 | 0.040 |
Why?
|
| Animals | 2 | 1992 | 1081 | 0.040 |
Why?
|
| Income | 1 | 2018 | 85 | 0.040 |
Why?
|
| Quality of Life | 1 | 2020 | 177 | 0.040 |
Why?
|
| Genomics | 1 | 2018 | 109 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2017 | 57 | 0.040 |
Why?
|
| Africa | 1 | 2017 | 376 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2018 | 656 | 0.030 |
Why?
|
| Hospitalization | 1 | 2018 | 418 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 1862 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 2013 | 52 | 0.030 |
Why?
|
| Breast Neoplasms, Male | 1 | 2013 | 1 | 0.030 |
Why?
|
| SEER Program | 1 | 2013 | 2 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1992 | 1 | 0.030 |
Why?
|
| Receptors, Cholinergic | 1 | 1992 | 1 | 0.030 |
Why?
|
| Receptors, Nicotinic | 1 | 1992 | 1 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 1992 | 1 | 0.030 |
Why?
|
| Calcium Channels | 1 | 1992 | 6 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1992 | 8 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 1992 | 9 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1991 | 2 | 0.020 |
Why?
|
| Myositis | 1 | 1991 | 4 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1991 | 49 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 507 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 1991 | 1 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1991 | 5 | 0.020 |
Why?
|
| Phosphorylation | 1 | 1991 | 6 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1991 | 13 | 0.020 |
Why?
|
| Cytosol | 1 | 1991 | 9 | 0.020 |
Why?
|
| Swine | 1 | 1991 | 49 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 54 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1991 | 36 | 0.020 |
Why?
|
| Ischemic Attack, Transient | 1 | 1999 | 2 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1999 | 12 | 0.010 |
Why?
|
| Echocardiography | 1 | 1999 | 100 | 0.010 |
Why?
|
| Dermatomyositis | 1 | 1991 | 2 | 0.010 |
Why?
|
| Immunologic Tests | 1 | 1991 | 7 | 0.010 |
Why?
|
| Seasons | 1 | 1991 | 154 | 0.010 |
Why?
|